[Security of hormone replacement therapy among postoperative patients with endometrial carcinoma: a Meta-analysis]

To systematically evaluate the security of hormone replacement therapy (HRT) among postoperative patients with endometrial carcinoma (EC).

A systematic review and Meta-analysis of studies on security of HRT among EC patients after operation was done by Revman 5.2 software. Studies were mainly searched from the CENTRAL, Medline, Embase, Ovid, Wanfang, CNKI databases.

A total of 7 studies with 2 038 stageⅠand stageⅡ endometrial carcinoma patients were included. The quality of 6 studies included were medium, and 1 study was high. The endometrial carcinoma patients on HRT did not have a statistically increased incidence in the EC recurrence (RR=0.69, 95%CI (0.42-1.15), P=0.16) and cancer-induced death (RR=0.55, 95%CI (0.25-1.21), P=0.14). Subgroup analysis for the start of HRT within 6 months from time of surgery group and only estrogen replacement therapy group found no statistical different in the risk of the EC recurrence and cancer-induced death, compared with control group. No statistically increased risk of the EC recurrence was observed for estrogen plus progestin replacement therapy group.

There is no statistical difference in the recurrence rate and cancer-induced death rate of EC whether the early stage postoperative patients used HRT or not.